Cuba Ventures Corp.

Pharmaceuticals

Cuba has developed a robust biotech and pharmaceutical industry. In fact, the nation has built some international acclaim for its pharmaceuticals. Recently, American scientists began clinical trials of a Cuban lung cancer vaccine. India, China and Brazil buy Cuban treatments for cholera, meningitis and cancer, among other diseases.

Cuba National pharmaceutical Groups are; biocen, biocubafarma, chemical pharmaceutical business group (quimefa), cimab, Cuban Centre for Genetic Engineering and Biotechnology (icgeb), Histotherapy center of Havana, labiofam, molecular immunology center.

Chemical Pharmaceutical Business Group (QUIMEFA) was formed by the Ministry of Basic Industry (MINBAS) to increase Cuba’s pharmaceutical research and production. Cuba invests in its pharmaceutical and health care sectors to bolster its pharmaceutical industry in the research and production of biotechnology products, generics and alternative medicines.

A few of the current drugs available;

CIMAVAX-EGF an oncology vaccine, developed in Cuba, for small cell lung cancer. Clinical trials are underway in USA, Canada, the United Kingdom, Malaysia and China.

Racotumomab is another anti-cancer vaccine. Both the CIMAVAX-EGF and the Racotumomab vaccines reduce the size of tumors and improve life expectancy.

Vidatox made by the Cuban pharmaceutical company Labiofam is a natural cancer treatment made from the venom of blue scorpions, a scorpion species endemic to Cuba. Currently joint ventures with Canada and China are underway.

Theraloc (nimotuzumab), another treatment for lung cancer and gastric cancer, developed by CIMAB a research company in Cuba. India, Japan, China and some countries in Latin America and Eastern Europe have already approved this drug for the treatment of oesophageal cancer, glioma, neck and head cancer.

Heberprot-P Cardiovascular DFU used for (diabetic foot ulcer) produced by Cuba’s Centre for Genetic Engineering and Biotechnology (ICGEB). It is now awaiting approvals in Europe and Latin America. At the current time, Heberprot-P is available in Turkey and is patented in 18 other countries.

Cholera and pneumococcal vaccines have been researched and developed by the Cuban firm BioCubaFarma.

Meningitis-B vaccine developed by Cuba’s Molecular Immunology Center BIOCEN, a pharmaceutical company in Bejucal, Mayabeque has developed a Hepatitis-B vaccine. It is currently undergoing trials in Cuba and Asia in partnership with Abivax, a French corporation.

The Histotherapy Center of Havana has been actively researching and producing drugs and cosmetics made from human placenta in the treatment of auto immune diseases such as vitiligo, psoriasis and alopecia.

While Cuba Ventures does not invest or participate in the Cuban pharmaceutical industry, management and advisors share over 80 years combined experience dealing with Cuba. Therefore, ventures in which a foreign entity wishes to enter or export from the Cuban pharmaceutical industry sector could be studied.
.